You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – Miraculins today said that it has successfully completed a two-part ISO certification audit conducted by the BSI Group.
NEW YORK (GenomeWeb News) – Miraculins yesterday said that it has received a C$1 million (US$986,000) non-convertible secured loan from Gretchen Ross.
The company said that if all warrants are exercised on or before expiration of the early exercise period, Miraculins expects to receive gross proceeds of around C$780,000.
Bloom Burton will provide financial modeling, an assessment of financing options, an evaluation of partnership opportunities, and other services.
The biomarker-based diagnostics firm sold 10.2 million units at C$.05 each.
The biomarker-based diagnostics firm will use the placement funding for R&D and corporate purposes.
Inverness, through its Biosite division, will develop and evaluate tests using Miraculins' panel of 35 biomarkers for placenta development and preeclampsia.
Miraculins will work with the Israel-based firm on a program to develop biomarker-based diagnostics for determining preeclampsia risk.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.